Document:

SERVICES
        AGREEMENT

       

      This
        SERVICES AGREEMENT, dated as of July 30, 2001 (the "Effective Date")
        by
        and between
        Response Genetics, Inc., a Delaware corporation ("Response"), and Taiho
Pharmaceutical
        Co., Ltd., a corporation organized under the laws of Japan, with a principal
        place of business at 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan
        ("Taiho") (Response and
        Taiho
        are sometimes hereinafter referred to as the "Parties").

       

      WHEREAS,
        Response is engaged in the business, among other things, of conducting
molecular-based
        tumor tissue analyses for use in guiding chemotherapy treatment for cancer
        patients
        using the Danenberg Tumor Profile Platform;

       

      WHEREAS,
        Taiho is engaged in the business of developing and marketing pharmaceutical
        and diagnostic products for use against cancer, as well as other diseases;
        and

       

      WHEREAS,
        Taiho desires that Response perform certain testing services using the DTP
        Platform for Taiho as the exclusive recipient of such services in Japan,
        and
        Response desires to do so;

       

      1. Definitions.

       

      (a) "Danenberg
        Tumor Profile Platform" or "DTP Platform" means the complex molecular
        analysis of specific molecular markers that provides tumor specific gene
        expression information obtained from a paraffin preserved sample, which can
        help
        physicians to plan and choose the most appropriate chemotherapy for a
        patient.

       

      (b) "Results"
        means the data on gene expression, molecular markers, and any other
        data generated by, or in the course of performing the Testing
        Services.

       

      (c) "Sample"
        means the tumor cell material supplied by Taiho to Response hereunder in
        the
        quantity, and meeting the requirements, specified in Schedule C, as necessary
        for Response to perform the Testing Service as contemplated
        hereunder.

       

      (d) "Term"
        means the period beginning on October 1, 2001 and ending on the second
        anniversary thereof, unless extended for an additional year by the Parties
        pursuant to paragraph
        10(d) herein.

       

      (e) "Territory"
        means the country of Japan.

       

      (f) "Testing
        Fee" means the amount specified in Schedule A, attached hereto, to be
        paid
        by Taiho to Response for performance of the Testing Services.

       

      (g) "Testing
        Services" means the specific services involving Response's application
        of the DTP Platform to Samples provided by Taiho, all pursuant to this Agreement
        and
        as
        more fully described in Schedule A, annexed hereto.

       

      
        	 	
                

              

      

       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      2. Appointment
        of Taiho; Territory.

       

      (a) During
        the Term (as defined in paragraph l (d) herein) and subject to the terms
        and
        conditions of this Agreement, Response hereby appoints Taiho as the exclusive
        purchaser of the
        Testing Services in Japan (for certain molecular markers, compounds and cancer
        types described as "Exclusive" in Exhibit A), and, as such, Response will
        not
        provide the Testing Services
        to another entity in Japan (the "Exclusivity"). Response further appoints
        Taiho
        as the non-exclusive
        purchaser of the Testing Services in Japan (for certain molecular markers,
        compounds
        and cancer types described as "Non-Exclusive” in Exhibit A). Taiho accepts such
appointment
        on the terms and conditions herein provided.

       

      (b) As
        described in Exhibit A, Response will promptly notify Taiho of new molecular
        markers, therapeutic compounds, and diseases for which the DTP Platform may
        be
        useful, and Taiho will have the right to include such new developments to
        the
        DTP Platform within its Exclusivity. The operation of such right, and Taiho's
        continuing Exclusive and Non- Exclusive rights regarding the DTP Platform
        are
        decribed in Exhibit A.

       

      3. Consideration.

       

      (a) Investment.
        As partial consideration for the rights, including Exclusivity, granted
        herein, Taiho shall purchase [***] dollars (U.S. $[***]) of shares of Series
        C
        Preferred Stock of Response, valued at the price per share of such Series
        C
        Preferred Stock sold by Response in its next round of equity financing, and
        shall promptly, upon Response's request, execute
        the subscription documents with respect thereto; provided, however, that
        if
        Response does
        not
        consummate its offering of Series C Preferred Stock (meaning that it shall
        complete all transactions for the purchase of shares of Series C Preferred
        Stock
        to investors other than Taiho) within
        ninety (90) days after the Effective Date with net cash proceeds to Response
        of
        at least [***] Dollars ($[***]), Taiho shall pay Response [***] dollars (U.S.
        $[***]) as an advance against the Testing Fees which accrue during the Term
        (the
        "Advance"), for Testing Services purchased in excess of the quarterly Minimum
        Testing Services quantities, and/or for Testing Services purchased subsequent
        to
        the Term, on a non-exclusive
        basis. If an advance against the Testing Fees has been made, and Response
        consummates
        an offering of Series C Preferred Stock, then Taiho may elect to convert
        the
unused
        balance of the advance into shares of Series C Preferred stock of Response,
        valued at the price
        per
        share of such Series C Preferred Stock sold by Response.

       

      (b) Testing
        Fees. Taiho shall pay Response the Testing Fee for each Testing Service
        purchased from Response during the Term. The Testing Fee shall cover performance
        of the Testing Service for two (2) genes in a Sample. For the testing of
        [***],
        the Testing Fee shall be an additional [***] dollars (US$[***]) above the
        amount
        listed in Schedule A. For each additional gene to be tested, the Testing
        Fee
        shall be an additional [***] dollars (US$[***]) above the amount listed in
        Schedule A.

       

      (c) Payment.

       

      (i)
        Response shall invoice Taiho on the last day of each calendar month during
        the Term for the number of Testing Services performed by Response during
        such
        month and
        for
        which Results were delivered to Taiho.

       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

          

        

        
          -2-

          
            

          

        

        
          
          

        

      

       

      (ii)
        Taiho shall pay amounts due to Response by wire transfer, or as otherwise
        mutually
        agreed upon by the Parties, within thirty (30) days after Taiho's receipt
        of the
        invoice sent
        by
        Response pursuant to paragraph 4(c) above. Payments shall be made in United
        States dollars
        to a bank account designated by Response.

       

      4. Minimum
        Testing Services. Taiho shall purchase from Response a minimum quantity of
        Testing Services during the Term as follows (as the case may be, the "Minimum
        Amount");

       

      (a) During
        the first calendar quarter of the Term, Taiho shall purchase from Response
        a minimum aggregate of [***] Testing Services;

       

      (b) during
        the second calendar quarter of the Term, Taiho shall purchase from Response
        a minimum aggregate of [***] Testing Services; and

       

      (c) in
        each
        calendar quarter during the remainder of the Term, Taiho shall purchase
        from Response a minimum aggregate of [***] Testing Services.

       

      In
        the
        event Taiho fails to purchase the Minimum Amount in a calendar quarter (the
        number of Testing Services constituting the difference between the Minimum
        Amount and the actual
        number of Testing Services purchased by Taiho in such period shall hereinafter
        collectively be
        referred to as the "Shortfall"), Taiho shall pay to Response an amount equal
        to
        the Shortfall times
        three [***] dollars (U.S. $[***]). Such amount, if any, shall be paid by
        Taiho
        to Response within thirty (30) days after Taiho's receipt of an invoice for
        such
        amount from Response
        following the end of each calendar quarter in which such Shortfall
        exists.

       

      For
        example:

      

      
        	
                Number
                  of Testing Services purchased in a calendar quarter:

              	 	 	
                [***]

              	 
	
                Minimum
                  Amount for such calendar quarter:

              	 	 	
                [***]

              	 
	
                Shortfall
                  ([***]):

              	 	 	
                [***]

              	 
	
                Amount
                  due Response ($[***]):

              	 	 	
                U.S.
                  $[***]

              	 

      

       

      5. Order
        and
        Delivery of Testing Services.

       

      (a)
        All
        Testing Services and any materials used in connection therewith shall be
        ordered, and all communications with the testing laboratory shall be performed,
        pursuant to (i) Response's
        instructions which will be communicated from time to time to Taiho by Response
        and
        (ii)
        the specifications described in Schedule C, annexed hereto, which may be
        changed
reasonably
        by Response upon reasonable prior notice to Taiho. Such instructions shall
        include information regarding shipment and delivery requirements for the
        Testing
        Service. Anything in this
        Agreement to the contrary notwithstanding, Response may process some or all
        of
        the Testing Services itself, or through any other designated and licensed
        laboratory, provided that such other laboratory
        is under an appropriate obligation of confidentiality.

       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

          

        

        
          -3-

          
            

          

        

        
          
          

        

      

    

    (b)
      Response shall provide Taiho with the Results for each Testing Service within
      seven
      (7)
      business days from Response's (or its designee's) receipt of Samples, at
      Response's designated laboratory. The Results shall include a gene expression
      value for any of the molecular
      markers set forth on Schedule A, accompanied by descriptive language in English.
      Response shall transmit the results of the Testing Services to Taiho via (i)
      facsimile or (ii) electronic transmission in a mutually agreeable format, at
      Taiho's option, and shall return separately any materials remaining from the
      Sample or derived therefrom during, the course of the
      Testing Service.

     

    6. Representations
      and Warranties.

     

    (a) Taiho
      hereby represents and warrants to Response that: Taiho is a corporation
      duly organized, validly existing and in good standing under the laws of Japan;
      Taiho has all corporate power and authority to execute this Agreement; when
      executed this Agreement will
      constitute a valid and legally binding agreement of Taiho enforceable against
      Taiho in accordance with its terms; and the execution and delivery of this
      Agreement, consummation of the
      transactions contemplated hereby, and the performance of the obligations of
      Taiho hereunder do
      not
      violate any law, rule or regulation or order, writ, injunction decree, of any
      court or governmental authority or other authority applicable to it and located
      in the Territory.

     

    (b) Response
      hereby represents and warrants to Taiho that:

     

    (i)
      Response is a corporation duly organized, validly existing and in good standing
      in the State of Delaware; Response has all corporate power and authority to
      execute this Agreement; when executed this Agreement will constitute a valid
      and
      legally binding agreement of Response enforceable against Response in accordance
      with its terms; and the execution and delivery of this Agreement and the
      consummation of the transactions contemplated, hereby, and the performance
      of
      the obligations of Response hereunder do not violate
      any law, rule or regulation or order, writ, injunction decree, of any court
      or
      governmental authority or other authority which is applicable to it or give
      rise
      to a default, right of termination, cancellation or acceleration or otherwise
      conflict with or result in a loss of contractual benefit to Response under
      the
      terms of any agreement or other instrument or obligation to which Response
      is
      a
      party or may be bound, or require any consent, approval or notice under any
      agreement to which Response is a party or may be bound;

     

    (ii)
      The
      performance of the Testing Services by Response shall in all respects
      comply with United States state and federal regulations.

     

    (c) Except
      as
      explicitly provided herein, the rights, information and materials provided
      by Response under this Agreement are WITHOUT REPRESENTATION OR WARRANTY
      OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY
      OTHER
      WARRANTY OR REPRESENTATION, EXPRESS OR IMPLIED. RESPONSE MAKES NO REPRESENTATION
      OR WARRANTY THAT EXERCISE OF THE RIGHTS GRANTED
      IN THIS AGREEMENT, OR USE OF ANY INFORMATION OR MATERIALS PROVIDED
      BY RESPONSE HEREUNDER, WILL NOT INFRINGE ANY THIRD-PARTY INTELLECTUAL
      PROPERTY OR OTHER PROPRIETARY RIGHT.

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

        

      

      
        -4-

        
          

        

      

      
        
        

      

    

    7. Ownership;
      Intellectual Property.

     

    (a) No
      Infringement. Taiho acknowledges that, as between the Parties, Response
      owns and/or controls, except as set forth in paragraph 7(b), (i) the Testing
      Services and all of the materials, other than Samples, which comprise the same;
      and any accompanying patent applications
      filed by Response. It is understood that neither Taiho nor any affiliate of
      Taiho shall
      acquire or claim any title to the Testing Services by virtue of this
      Agreement.

     

    (b) Ownership
      of Results. Notwithstanding any other provision hereunder, Taiho
      shall own all right, title and interest in and to the Results, and all
      intellectual property rights
      therein or thereto, all of which Response hereby assigns to Taiho. Response
      agrees to hold Results
      and Samples in confidence, and agrees not to use for any purpose and not to
      disclose to third parties in any manner Results or Samples without the prior
      written consent of Taiho.

     

    (c) Use
      of
      Name. Each Party agrees that it will not, during the Term, use the name
      of
      the other Party or any reproduction, counterfeit, copy or colorable imitation
      thereof, in any way, except to indicate, as specifically authorized therein,
      that Taiho has exclusive rights in Japan
      to
      order the Testing Services.

     

    (d) Sublicense.
      Within thirty (30) days after the Effective Date, Response will
      submit to the University of Southern California a written request to approve
      a
      non-exclusive sublicense
      of the Testing Services to Taiho for distribution in Japan during the Term,
      which sublicense Taiho will not exercise unless and until Taiho terminates
      this
      Agreement pursuant to Paragraph
      10(b). Response will cooperate with taiho as necessary to effectuate the
      foregoing, and
      Response and Taiho will execute such documents as are necessary to effectuate
      the foregoing.
      Taiho's sublicense will include other intellectual property owned or controlled
      by Response
      necessary or useful to perform the Testing Services.

     

    8. Indemnification

     

    (a) Taiho
      shall indemnify and hold harmless Response and its officers, directors,
      stockholders, independent contractors, employees and agents from any liability,
      loss, damages, expense (including, without limitation, reasonable attorneys'
      fees and disbursements) or claim by a third party resulting from or arising
      out
      of: (i) any act or omission by Taiho in the performance of its obligations
      hereunder or due to any breach by Taiho of its warranties in paragraph
      6; (ii) any actual or alleged personal injury or property damage arising or
      resulting out of
      the
      distribution of the Testing Services by Taiho in the Territory; (iii) any actual
      or alleged false
      advertising or unfair competition by Taiho in its distribution, marketing,
      or
      exploitation of Testing
      Services; and (iv) any Regulatory Challenge (as defined in paragraph 9(d)
      below).

     

    (b) Response
      shall indemnify and hold harmless Taiho and its officers, directors,
      stockholders, independent contractors, employees and agents from any liability,
      loss, damages, expense (including reasonable attorneys' fees and disbursements)
      or claim by a third party:
      (i) resulting from or arising out of any act or omission by Response in the
      performance of its obligations hereunder; (ii) due to any breach by Response
      of
      its warranties in paragraph 6; or (iii) that the use, performance or
      distribution of the Testing Services infringes or misappropriates the
      intellectual property rights of a third party.

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

        

      

      
        -5-

        
          

        

      

      
        
        

      

    

     

    (c) Notice.
      In the event of any claim, action or proceeding for which either Party
      is
      entitled to indemnity hereunder, such Party shall promptly notify the other
      Party of such matter
      in
      writing. The indemnifying Party shall then promptly, at its sole cost, assume
      responsibility
      for and shall have control of such matter, including settlement negotiations
      and
      the institution
      and defense of any legal proceedings, provided that the indemnified Party shall
      retain the right to be represented, at its sole expense, by separate counsel.
      The indemnified Party shall have the right to approve or disapprove any proposed
      settlement, which approval shall not be unreasonably withheld. If the
      indemnifying Party does not make a timely election to undertake the
      good
      faith defense or settlement of the claim as aforesaid, or if the indemnifying
      Party fails to proceed
      with the good faith defense or settlement of the matter after making such
      election, then, in either such event, the indemnified Party shall have the
      right
      to contest, settle or compromise the claim at its exclusive discretion, at
      the
      risk and expense of the indemnifying Party to the full extent set forth in
      paragraphs 8(a) or 8(b), as the case may be.

     

    (d) Regulatory
      Action. In the event of a challenge or protest relating to this Agreement
      by any U.S. or other governmental agency (including, without limitation,
      Japanese or any subdivision thereof), any U.S. state attorney general or any
      other regulatory body alleging false or misleading advertising and/or labeling
      provisions and/or adulterated or misbranded product
      or other matter referred to in paragraph 7(a)(ii) above ("Regulatory
      Challenge"), Response
      shall (to the extent permitted by law or such governmental agency) have the
      right to participate in any settlement proceedings related thereto and to be
      consulted by Taiho regarding such
      settlement.

     

    9. Insurance.
      Response agrees to obtain, at its sole cost and expense, no less than
U.S.
      Ten
      Million Dollars (U.S. $10,000,000) umbrella comprehensive general liability
      insurance, including
      product liability coverage, and advertiser's liability coverage, with Taiho
      named as an additional
      insured. Response shall submit certificates of such insurance to Taiho that
      includes a thirty (30) day prior written notice of cancellation provision.
      Response shall keep such policies in force during the Term and for at least
      three (3) years thereafter, and, upon Taiho's request, shall
      submit evidence of renewal prior to the expiration of the original term of
      insurance and any renewal
      term thereafter.

     

    10. Termination.

     

    (a)
      Response shall, at its option, have the right, in addition to any other rights
      it may
      have
      hereunder, at law or otherwise, to terminate this Agreement:

     

    (i)
      in
      the event of a material breach by Taiho of this Agreement which is not cured
      within forty-five (45) days of receipt of written notice of such breach from
      Response;

     

    (ii)
      upon
      the occurrence of any of the following events:

     

    (A) Taiho
      becomes insolvent, however evidenced, or makes an assignment for
      the
      benefit of creditors; or

     

    (B) Taiho
      files a petition seeking relief under any provision of any Japanese
      statute now or hereafter in effect affording relief to debtors, or any such
      application or petition is filed against Taiho, which application or petition
      is
      not dismissed or withdrawn within forty-five
      (45) days from the date of its filing; or

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

        

      

      
        -6-

        
          

        

      

      
        
        

      

    

     

    (C)
      the
      appointment of a receiver for Taiho, and such receivership proceedings
      are not dismissed within forty-five (45) days after the receiver's appointment;
      or

     

    (D)
      the
      commencement by Taiho of liquidation, dissolution or winding-up proceedings,
      or the commencement against Taiho of a proceeding to liquidate, wind-up or
      dissolve Taiho which proceeding is not dismissed within forty-five (45)
      days.

     

    (b) Taiho
      shall have the right, in addition to any other rights it may have hereunder,
      of law or otherwise to terminate this Agreement:

     

    (i)
      in
      the event of a material breach by Response of this Agreement which breach
      is
      not cured within forty-five (45) days of receipt of written notice of such
      breach from Taiho;
      or

     

    (ii)
      upon
      the occurrence of any of the following events:

     

    (A) Response
      becomes insolvent, however evidenced, or makes an assignment
      for the benefit of creditors; or

     

    (B) Response
      files a petition seeking relief under any provision of the Federal
      Bankruptcy Code or any other federal or state statute now or hereafter in effect
      affording relief
      to
      debtors, or any such application or petition is filed against Response, which
      application or
      petition is not dismissed or withdrawn within forty-five (45) days from the
      date
      of its filing; or

     

    (C) the
      appointment of a receiver for Response or for all or a substantial part
      of
      the assets of Response and such receivership proceedings are not dismissed
      within forty-five
      (45)
      days after such receiver's appointment; or

     

    (D) Response
      ceases to provide or conduct Testing Services or similar services
      using the DTP Platform; or

     

    (E) the
      commencement by Response of liquidation, dissolution or winding-up
      proceedings, or the commencement against Response of a proceeding to liquidate,
      wind-up or dissolve Response, which proceeding is not dismissed within
      forty-five (45) days.

     

    (c) For
      purposes of this Paragraph 10, a failure by Response to timely perform
Testing
      Services and deliver the Results to Taiho in accordance with the terms of this
      Agreement shall
      constitute a material breach of this Agreement.

     

    (d) The
      term
      of this Agreement may be extended by an additional one (1) year period if (i)
      Taiho provides written notice to Response, not less than one hundred eighty
      (180) days prior to the second anniversary of the Effective Date, of its intent
      to so extend the Term, and
      (ii)
      within thirty (30) days of the date of such notice, Response does not decline,
      in writing to Taiho,
      to
      extend the Term for an additional year. In the event of such extension, Response
      shall continue to provide the Testing Services under the terms and conditions
      herein.

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

        

      

      
        -7-

        
          

        

      

      
        
        

      

    

    (e) It
      is
      understood that as of the Effective Date, Response does not own or control
      an
      issued patent that would necessarily prevent the use of a method substantially
      similar to that used in the DTP Platform for testing samples from Japanese
      patients (i.e. patients being treated
      in Japan). Accordingly, in the event that a third party actually provides such
      testing services using such a method to evaluate or diagnose Japanese patients,
      Response agrees as follows:
      (i) if Taiho provides notice of the foregoing prior to the second anniversary
      of
      the Effective
      Date, Response will negotiate in good faith a downward adjustment to the terms
      of this Agreement
      to reflect such competition as the parties reasonably agree; or (ii) if the
      Term
      of this Agreement
      has been extended under paragraph 10(d) and Taiho provides notice of the
      foregoing during
      the third year of the Term, Response will negotiate in good faith a downward
      adjustment to
      the
      terms of this Agreement to reflect such competition as the parties reasonably
      agree and the obligation
      to purchase the Minimum Amount under pargraph 4 shall no longer apply.
However,
      if the parties are unable to agree on mutually acceptable terms for the
      remaining Term of
      this
      Agreement, then Taiho shall have the right, upon notice to Response and at
      Taiho's sole discretion,
      to either (i) terminate this Agreement upon notice to Response; or (ii) if
      a
      third party actually provides such services to test samples from Japanese
      patients at a price lower than the Testing
      Fee for any type of test hereunder, terminate its obligations under paragraph
      4
      applicable to
      the
      remainder of the Term of this Agreement. In the event Taiho elects (ii) above,
      Taiho's appointment
      under paragraph 2 as the exclusive purchaser of the Testing Services in Japan
      for certain molecular markers, compounds and cancer types described as
      "Exclusive" in Exhibit A shall become non-exclusive during the balance of the
      third year of the Term.

     

    (f) Termination
      or expiration of this Agreement shall not relieve either Party of its
      obligations relating to Testing Services ordered or rendered prior to the date
      of such termination.

     

    (g) In
      the
      event of termination or expiration, Taiho will be obligated to pay the
balance
      of any Testing Service Fees incurred as of the date of termination, and Response
      will be obligated to complete the Testing Service on any Samples received by
      Response (or its designee) within
      ten (10) days after the date of such termination or expiration. If Taiho is
      the
      terminating Party,
      the uncredited amount of the Advance paid under paragraph 3(a) shall be
      converted by Response into shares of Series C Preferred Stock of Response at
      a
      conversion price equal to the price per share of such Series C Preferred Stock
      sold by Response in its next round of equity financing,
      if concluded, or if not concluded, into shares of Series B Preferred Stock
      of
      Response at
      a
      conversion price of $[***] per share. Notwithstanding the foregoing, termination
      of this Agreement
      for any reason shall not release either Party from any liability which, at
      the
      time of such
      termination, has already accrued to the other Party or which is attributable
      to
      a period prior to such termination, nor preclude either Party from pursuing
      any
      rights and remedies it may have hereunder
      or at law or in equity with respect to any breach of this
      Agreement.

     

    (h)
      In
      the event of any termination of this Agreement by Taiho pursuant to Paragraph
      10(b), Taiho may, at its sole option, elect either to: (1) exercise its license
      regarding Testing
      Services granted under Paragraph 7(d); or (ii) have Dr. Peter Danenberg and/or
      Kathleen Danenberg
      provide the Testing Services for Taiho in the same manner as Response provides
      hereunder, as agrees to in the letter attached as Schedule D, and for which
      Response grants any rights
      and licenses necessary to conduct such Testing Services, provided
      that, Taiho
      shall pay the costs,
      direct and indirect, for equipment, supplies and salaries for such Testing
      Services as performed
      by either of the Danenberg's, in the form of a research grant or contract which
      conforms
      to the specifications required by the University of Southern California and
      except for the
      price
      paid by Taiho, both of the Danenberg's shall provide the Testing Services in
      accordance
      with the same terms and conditions as Response performed such Testing Services
      hereunder.

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

        

      

      
        -8-

        
          

        

      

      
        
        

      

    

     

    (i)
      In
      the event of any termination or expiration of this Agreement, Response will
      return
      all unused Samples and materials derived from Samples and all copies of Results
      to Taiho. Paragraphs
      1, 6, 7(a), 7(b), 8, 10(e)-(h), 11 and 12 will survive termination or expiration
      of this Agreement
      for any reason. Paragraph 7(d) will survive any termination under paragraph
      10(b).

     

    11.
      Notices. All notices and consents required or permitted hereunder (all of the
      foregoing
      hereinafter collectively referred to as "Communications") shall be in writing
      and shall be deemed to have been duly given and received upon receipt, if
      delivered (a) personally with receipt acknowledged, (b) by registered or
      certified mail or equivalent, return receipt requested, postage prepaid, (c)
      mailed by overnight or international courier for next day or second day
      delivery, as the case may be, in each case addressed to the Parties at their
      respective addresses set
      forth
      below or to such other address as any Party shall hereafter specify by
      Communication to the
      other
      Party, or (d) by telecopy to the number set forth below or to such changed
      number as any Party shall hereafter specify by Communication to the other
      Party:

     

    
      	
              If
                to Response to: 

            	 	
              Response
                Genetics, Inc.

              1180
                Avenue of the Americas

              Suite
                1412

              New
                York, NY

              Attn:
                Chief Executive Officer

            
	 	 	 
	
              with
                a copy to:

            	 	
              Blank
                Rome Tenzer Greenblatt LLP

              405
                Lexington Avenue 

              New
                York, NY 10174

              Attn:
                Emanuel J. Adler, Esq.

              Telecopier
                No.: (212) 885-5001

            
	 	 	 
	
              If
                to Kathleen Danenberg to: 

            	 	
              Kathleen
                Danenberg

              Vice
                President & Chief Scientific Officer

              Response
                Genetics, Inc.

              1640
                Marengo Street; 6th Floor

              Los
                Angeles, CA 90033

            
	 	 	 
	
              If
                to Taiho to:

            	 	
              Taiho
                Pharmaceutical Co., Ltd.

              1-27
                Kandanishiki-cho, Chiyoda-ku, Tokyo
                101-8444, Japan 

              Attn:
                [***] 

              Telecopier
                No.: +81-3-3291-4303

            

    

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

        

      

      
        -9-

        
          

        

      

      
        
        

      

    

     

    
      	
              with
                a copy to:

            	 	
              Wilson
                Sonsini Goodrich & Rosati

              One
                Market

              Spear
                Tower, Suite 3300 
San Francisco, CA 94105 
Attn: David R. Boyko,
                Esq. 
Telecopier No.: (415)
                947-2099

            

    

     

    12. Entire
      Agreement and Waiver. This Agreement and the Secrecy Agreement dated March
      14,
      2001, and any amendments to the Secrecy Agreement subsequently executed by
      both
      parties, contain the entire agreement between the Parties with respect to the
      subject matter hereof and supersedes all previous agreements or arrangements
      between the Parties relating to the subject matter hereof. No purported waiver
      by any Party of any breach by the others of any of its obligations, agreements
      or covenants hereunder, or any part thereof, shall be effective unless
made
      in
      writing, signed by the Party sought to be bound thereby, and no failure to
      pursue or elect any
      remedy with respect to any default under or breach of any provisions of this
      Agreement, or any part thereof, shall be deemed to be a waiver of any other
      or
      subsequent, similar or different default or breach, or any election of remedies
      available in connection therewith, nor shall the acceptance or receipt by either
      Party of any money or other consideration due to it under this Agreement, with
      or without knowledge of any breach hereunder, constitute a waiver of any
      provision of this Agreement with respect to such or any other
      breach.

     

    13. Force
      Majeure. If the performance of this Agreement or any obligation, action or
      transaction under this Agreement by either Party is hindered or prevented
      ("Impeded") by act of God, action of the elements, fire, accident, riot, strike,
      work stoppage or other labor disturbance, war,
      invasion, civil commotion, enactment of laws or other casualty or cause, whether
      similar or dissimilar,
      beyond the reasonable control of the Party required to perform and without
      such
      Party's fault or negligence (each a "Force Majeure Condition"), performance
      by
      that Party to the extent so Impeded shall be excused during the period of the
      Force Majeure Condition; provided, however,
      that no Force Majeure Condition shall relieve Taiho of the obligation to pay
      for
      Testing Services
      which have already been completed by Response; and further provided that, to
      the
      extent Response or its designee is Impeded by a Force Majeure Condition from
      performing the Testing Services, Taiho's obligation to purchase Testing Services
      from Response and to pay the Minimum Testing Services Fees shall be suspended
      for the same period of time.

     

    14. Assignment;
      Binding Effect. Except as otherwise provided herein, neither Party may
      assign this Agreement without the prior written consent of the other Party,
      except that either Party
      may
      assign this Agreement without prior consent to an entity that acquires all
      or
      substantially all of the business or assets of that Party (or that portion
      thereof to which this Agreement relates), in each case whether by merger,
      acquisition, or otherwise, provided that such
      assignee agrees in writing to be bound by the terms and conditions of this
      Agreement. This Agreement
      shall inure to the benefit of and be binding upon the Parties hereto and their
      respective
      successors and permitted assigns. Nothing in this Agreement, express or implied,
      is intended
      to or will confer on any person other than the Parties, and their respective
      successors and
      permitted assigns, any benefits, rights, remedies, obligations or liabilities
      under, or by reason of, this Agreement.

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

        

      

      
        -10-

        
          

        

      

      
        
        

      

    

    

      15. Independent
        Contractors. In all matters relating to this Agreement, the Parties shall
        be
        deemed independent contractors.- The Parties expressly disclaim any intention
        to
        create a
        partnership, agency or joint venture pertaining to the subject matter of
        this
        Agreement.

       

      16. Press
        Release. Except as otherwise required by law or applicable regulation, and
        except
        for disclosures made by Response or Taiho with respect to any private or
        public
        offering of
        its
        securities, neither Party shall issue any press release or make any public
        announcement relating to the subject matter of this Agreement without the
        prior
        written approval of the other Party, which shall not be unreasonably withheld
        or
        delayed.

       

      17. Governing
        Law/Submissions to Jurisdiction. This Agreement shall be governed and
        construed in all respects by the laws of the State of New York applicable
        to
        contracts entered into
        and
        to be wholly performed therein, without regard to its conflicts of laws
        principles. Each of
        the
        Parties hereby agrees that any suit, action or proceeding arising out of
        this
        Agreement or the Secrecy Agreement may be instituted against it in the United
        States District Court for the Southern
        District of New York. Each of the Parties expressly consents to personal
        jurisdiction in the
        State
        of New York with respect to such suit, action or proceeding. Each Party
        irrevocably and unconditionally
        waives any objection to the jurisdiction and venue required in this Paragraph
        18, and agrees not to plead or claim in any such court that any such suit,
        action, or proceeding has been brought in an inconvenient forum.

       

      18. Severability.
        If one or more of the provisions contained in this Agreement shall be
        determined to be invalid or unenforceable by a court of competent jurisdiction
        or by any other legally
        constituted body having the jurisdiction to make such determination, the
        validity and enforceability of the remaining provisions shall not in any
        way be
        affected or impaired thereby and said provision shall be (only with respect
        to
        the operation thereof in the particular jurisdiction
        in which such adjudication is made) construed by limiting and reducing it
        so as
        to be enforceable
        to the extent permissible.

       

      19. Headings;
        Word Meanings. The headings preceding the text of the various provisions
        of this Agreement are for convenience of reference only and are not intended
        to
        define, limit or in any other way describe the scope of this Agreement or
        the
        intent of the provisions
        hereof. The singular shall include the plural and the masculine gender shall
        include the
        feminine and neuter, and vice versa, unless the context otherwise
        requires.

       

      20. Further
        Actions. At any time and from time to time, each Party agrees, without
further
        consideration, to take such actions and to execute and deliver such documents
        as
        may be reasonably necessary to effectuate the purposes of this
        Agreement.

       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

          

        

        
          -11-

          
            

          

        

        
          
          

        

      

    

     

    21.
      Counterparts. This Agreement may be executed in any number of counterparts,
      each
      of
      which shall be deemed an original, but all of which together shall constitute
      one and the same
      instrument.

     

    IN
      WITNESS WHEREOF, this Agreement has been executed and delivered by the
      Parties hereto on the date and year first above written.

     

    
      	 	 	 	 
	
              RESPONSE
                GENETICS, INC.

            	 	 	
              TAIHO
                PHARMACEUTICAL CO., LTD.

            
	 	 	 	 
	 	 	 	 
	By: 
 	 	 	By: 
 
	
              
                

              

              Name:
                Mr. Larry C Heaton II

              Title:
                President and CEO

            	 	 	
              
                

              

              Name:
                Mr. Akira Akazawa

              Title:
                Senior Managing Director

            
	 	 	 	 
	
              I
                agree to abide by the terms and obligations of Paragraph
                10(h).

            
	 	 	 	 
	 	 	 	 
	 	 	 	By: 
 
	 	 	 	
              
                

              

              Name: Kathleen
                Danenberg

            

    

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

        

      

      
        -12-

        
          

        

      

      
        
        

      

       

    

    SCHEDULE
      A

     

    EXCLUSIVITY

     

    As
      of the
      Effective Date, Response grants Taiho the right to be the exclusive purchaser
      in
Japan
      of
      tests and testing services based upon the DTP Platform using gene expression
      for
      the foregoing (collectively referred to as the "Field"):

     

    1) for
      any
      one or combination of the following molecular markers: [***]; or

     

    2) [***];
      or

     

    3) relevant
      to the diagnosis or therapeutic treatment of precancerous and cancerous
      diseases of the [***].

     

    NON-EXCLUSIVITY

     

    As
      of the
      Effective Date, Response grants Taiho the right to be a non-exclusive purchaser
      in
      Japan
      of tests and testing services based upon the DTP Platform using gene expression
      not covered by an Exclusivity agreement:

     

    1)
      for
      any one or combination of molecular markers other than those for which
      Taiho has Exclusivity; or

     

    2) relevant
      to the therapeutic use of any compound or biological product against
cancer
      other than those compounds for which Taiho has Exclusivity; or

     

    3) relevant
      to the diagnosis or therapeutic treatment of precancerous and cancerous
      diseases other than those for which Taiho has Exclusivity.

     

    NEW
      MOLECULAR MARKERS, ANTI-CANCER AGENTS, DTP USES

     

    Response
      will notify Taiho from time to time of new molecular markers, anti-cancer
agents
      and/or uses of the DTP Platform as they are developed and validated by
      Response, In such
      event, Exclusivity with respect to such new molecular markers, anti-cancer
      agents and/or uses
      will
      be determined by mutually agreed upon pricing, milestones, minimums or other
      criteria to
      be
      negotiated and agreed to by the Parties. In the event the parties fail to
      mutually agree upon such
      pricing, milestones, minimums or other criteria within thirty (30) days of
      Taiho's receipt of notice
      of
      such new molecular markers, anti-cancer agents and/or uses, Response shall
      have
      the right to engage any other third party as an exclusive distributor of the
      Testing Services outside the Field with respect to such new molecular markers,
      anti-cancer agents and/or uses; provided that Taiho will retain non-exclusive
      rights to such new molecular markers, anti-cancer agents and/or
      uses within the Field in Japan. The following examples illustrate the operation
      of such non-exclusivity:

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

        

      

      
        -13-

        
          

        

      

      
        
        

      

    

    1) Taiho
      and
      Response do not agree on terms of Exclusivity for new molecular marker
[***].
      Therefore, Taiho retains a non-exclusive right to provide the DTP in Japan
      using
[***]
      in
      the Field (i.e., for precancerous and cancerous diseases of the [***],
or
      as
      relevant to therapeutic use of [***] compounds (either alone or in combination
      with other compounds or therapies), or with molecular markers [***]). Response
      may grant a third party exclusive distribution rights for such new molecular
      marker [***] in Japan outside the Field
      (i.e., as relevant for therapeutic use of compounds other than, and not used
      in
      combination with,
      [***] or as relevant for precancerous and cancerous diseases of other than
      the
      [***]);
      provided, however, that Response may not grant a third party distribution rights
      in Japan to use [***] in the Field (i.e., for precancerous and cancerous
      diseases of the [***],
      or as
      relevant to therapeutic use of [***] compounds (either alone or in combination
      with other compounds or therapies), or with molecular markers
      [***]).

     

    2) Taiho
      and
      Response do not agree on terms of Exclusivity for new use of the DTP
with
      respect to [***]. Thereafter, Taiho retains a non-exclusive right to provide
      the
      new use
      of
      the DTP in Japan within the Field (i.e., as relevant to therapeutic use of
      [***]
      compounds (either alone or in combination with other compounds or therapies),
      or
      for molecular markers [***],
      or
      as relevant to precancerous and cancerous diseases of the [***]). Response
      may grant a third party exclusive distribution rights for such new use of the
      DTP in Japan outside the Field (i.e., as relevant for therapeutic use of
      compounds other than, and not used in combination with, [***] or as relevant
      for
      precancerous and cancerous diseases of other than the [***]); provided, however,
      that Response may not grant a third party distribution rights in Japan to such
      new use of the DTP in the Field (i.e., as relevant to therapeutic use of 5-Fu
      compounds (either alone or in combination with other compounds or therapies),
      or
      for molecular markers [***], or for precancerous and cancerous diseases of
      the
      [***]).

     

    3) Taiho
      and
      Response do not agree on terms of Exclusivity for use of the DTP with respect
      to
      [***]. Therefore, Taiho retains a non-exclusive right to use the DTP as relevant
      to use of [***] in Japan within the Field (i.e., as relevant for precancerous
      and cancerous diseases of the [***], or for therapeutic use of [***] compounds
      (either alone or in combination with other compounds or therapies) or for
      molecular markers [***]). Response may grant a third party exclusive
      distribution rights in Japan outside the Field (i.e., as relevant
      for therapeutic use of compounds other than, and not used in combination with,
      [***], or as
      relevant for precancerous and cancerous diseases of other than the [***]);
      provided, however, that Response may not grant a third party distribution rights
      in Japan to use the DTP with [***] in the Field (i.e., as relevant for
      precancerous and cancerous diseases of the [***], or for therapeutic use in
      combination with [***] compounds, or for molecular markers [***]).

     

    Further,
      until such time as Response actually enters into an agreement with a third
      party
      for exclusive rights outside the Field in Japan with respect to such new
      molecular markers, anti-cancer agents and/or uses of the DTP Platform, Taiho
      will have the non-exclusive right in Japan to
      purchase tests and testing services based upon such new molecular markers,
      anti-cancer agents and/or
      uses of the DTP Platform, whether inside or outside the Field.

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

        

      

      
        -14-

        
          

        

      

      
        
        

      

    

     

    SCHEDULE
      B

     

    TESTING
      SERVICE FEES

     

    During
      each calendar quarter of the Term, the Testing Service Fee shall be as
      follows:

     

    
      	
              Number
                of Testing Services purchased
                by Taiho during each
                calendar quarter of the Term

            	 	
              Testing
                Service Fee

            	 
	
              [***]

            	 	
              $

            	
              [***]

            	 
	
              [***]

            	 	
              $

            	
              [***]

            	 

    

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

        

      

      
        -15-

        
          

        

      

      
        
        

      

    

     

    SCHEDULE
      C

     

    INSTRUCTIONS
      AND SPECIFICATIONS FOR SENDING TISSUE

    SAMPLES
      FOR RESPONSE GENETICS' DANENBERG TUMOR

    PROFILE
      FOR COMMERCIAL PROCESSING

     

    1. Patient
      Information

     

    A. Taiho
      unique I.D. No.

     

    B. For
      each
      specimen provided, a diagnosis or provisional diagnosis supplied by a physician
      (pathologist or other qualified physician) certified in anatomical pathology,
      which diagnosis
      shall include (i) the type of tumor, including histomorphology and
      histopathology, (ii) source organ of the specimen, (iii) whether the specimen
      is
      primary or metastatic, and (iv) if the specimen
      is metastatic, the origin of the primary tumor.

     

    2. Sample
      Preparation

     

    (1) Sample
      to
      be processed should correlate with stage and site to be treated.

     

    (2) Cut
      one 5
μM section, mount on glass slide.

     

    (3) Cut
      four
      10 μM sections,
      mount on four separate regular glass slides. Glass slides should
      be
      regular glass, uncoated and uncharged. Do not bake slides and do not use
      coverslip. Slides
      must contain a sufficient quantity of tumor tissue to be successfully
      microdissected.

     

    (4) Send
      above referenced samples or specimens by overnight delivery in approved slide
      holder, placed in a bubble-lined envelope and in a Federal Express Diagnostic
      Specimen Envelope,
      to the laboratory designated by Response at Response's direction.

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

        

      

      
        -16-

        
          

        

      

      
        
        

      

    

     

    
      
        	 	UNIVERSITY OF SOUTHERN
                CALIFORNIA
		Keck
                School of
                Medicine
	 	 	 
	
                Department of Biochemistry and Molecular
                  Biology

                USC/Nom's Comprehensive Cancer
                  Center

              	 	 
	 	 	 
	
                Peter
                  V. Danenberg, Ph.D.

                Professor
                  of Biochemistry and Molecular Biology

              	 	 

      

    

     

    SCHEDULE
      D 

     

    July
      23,
      2001

     

    [***]

    Manager

    Product
      Research & Licensing

    Taiho
      Pharmaceutical Co Ltd

    1-27
      Kandanishiki-cho, Chiyoda-ku,

    Tokyo
      101-8444, Japan

     

    Dear
      [***]:

     

    This
      is
      to confirm our commitment that, in the event of a termination in accordance
      with
paragraph
      10 (b) by Taiho of the Services Agreement of June, 2001 between Taiho
Pharmaceutical
      Co, Ltd., and Response Genetics, Inc., we will undertake a research project
      for
Taiho
      in
      which we will provide the Testing Services in the same manner described in
      the
Services
      Agreement, provided that Taiho pays the costs, direct and indirect, for
      equipment, supplies
      and salaries for such Testing Services in the form of a research grant or
      contract which conforms
      to the specifications required by the University of Southern
      California.

     

    Best
      regards,

    
      	 	 	 	 
	By:  
              	 	 	By:  
              
	
              
                

              

              
                Peter
                  Danenberg, PhD 

              

            	 	 	
              
                

              

              Kathleen
                Danenberg

            
	
            	 	 	
            

    

    1441
      Eastlake Ave., Rm. 5318

    Los
      Angeles, CA 90033

    VOX:
      323-865-0518

    FAX:
      323-865-0105

    email:
      pdanenbe@hsc.usc.edu

    

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

        

      

      
        -17-

        
          

        

      

      
        
        

      

    

    SCHEDULED

     

    Letterhead
      of the USC Laboratory of Dr. Peter Danenberg

     

    June
      ,
      2001

     

    [***]

    Manager

    Product
      Research & Licensing

    Taiho
      Pharmaceutical Co Ltd

    1-27
      Kandanishiki-cho, Chiyoda-ku,

    Tokyo
      101-8444, Japan

     

    Dear
      [***]:

     

    This
      is
      to confirm our commitment that, in the event of a termination in accordance
      with
      paragraph 10 (b) by Taiho of the Services Agreement of June, 2001 between Taiho
      Pharmaceutical
      Co, Ltd., and Response Genetics, Inc., we will undertake a research project
      for
Taiho
      in
      which we will provide the Testing Services in the same manner described in
      the
      Services Agreement, provided that Taiho pays the costs, direct and indirect,
      for
      equipment, supplies
      and salaries for such Testing Services in the form of a research grant or
      contract which conforms
      to the specifications required by the University of Southern
      California.

     

    Best
      regards,

    
      	 	 	 	 
	By:	 	 	By:
	
            	 	 	
            
	Peter Danenberg, PhD	 	 	Kathleen
              Danenberg

    

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

        

      

      
        -18-

        
          

        

      

      
        
        

      

    

     

    September
      30, 2004

     

    [***]

    Director
      of Product Research & Licensing

    Taiho
      Pharmaceutical Co., Ltd.

    1-27,
      Kandanishiki-cho

    Chiyoda-ku,
      Tokyo, 101-8444 

    Japan

     

    
      	
            	Re:	
              Services
                Agreement ("Agreement") dated July 30, 2001 between Response
                Genetics,
                Inc. ("Response") and Taiho Pharmaceutical Co., Ltd.
                ("Taiho")

            

    

     

    Dear
      [***]:

     

    This
      letter reflects Response and Taiho's mutual agreement to modify the terms of
      the
      above referenced
      Agreement as follows:

     

    
      	 	
              1.

            	
              All
                capitalized terms not herein defined shall have the meaning set forth
                in
                the Agreement.
                Except as set forth in this letter, the terms and conditions of the
                Agreement shall
                continue in full force and effect. Unless otherwise stated, "Paragraph"
                shall refer to paragraphs of the Agreement and "Item" the items of
                this
                letter.

            

    

     

    
      	 	
              2.

            	
              Notwithstanding
                Paragraph 1(d), the "Term" shall mean the period beginning on October
                1,
                2001 and ending on October 1, 2007, unless extended in accordance
                with
                Item 4 below.

            

    

     

    
      	 	
              3.

            	
              During
                the period from October 1, 2004 through October 1, 2007 (the "Extension
                Period"), the terms and conditions for the supply of Testing Services
                by
                Response to Taiho,
                including the Testing Fees and Minimum Amounts, shall be the same
                as set
                forth in the Agreement.

            

    

     

    
      	 	
              4.

            	
              The
                Term may be extended for additional two (2) year periods, each time
                upon
                the mutual
                agreement of the Parties. The parties shall begin discussions concerning
                this subsequent extension in good faith upon either Party's request
                within
                ninety (90) days prior to the conclusion of the then effective Term.
                In
                the event the Parties cannot agree on
                any such extension of the Term, then upon the request of Taiho, Taiho
                shall have an irrevocable
                non-exclusive right to purchase all Testing Services from Response
                at a
                price equal to the Testing Fee or the then-current worldwide average
                net
                sales price charged by Response
                for the respective Testing Service, whichever is
                lower.

            

    

     

    
      	 	
              5.

            	
              Response
                confirms that it will promptly obtain the approval of the University
                of
                Southern California
                ("USC") as set forth in Paragraph 7(d) (and the consent of USC to
                have
                Taiho's sublicense rights from USC remain in effect, whether as a
                sublicense or a direct license, after any termination of the agreement
                between USC and Taiho). Response shall hereby grant Taiho a non-exclusive
                sublicense under the intellectual property licensed from
                USC to Response and a non-exclusive license under any other necessary
                intellectual property
                owned or controlled by Response, in Japan, to make, use and practice
                the
                Testing
                Services and the DTP Platform, solely for research purposes, on Taiho's
                behalf or on
                the behalf of its research collaborators, including to have such
                activities performed by subcontractors.
                This non-exclusive sublicense and license specifically excludes the
                right
                to
                offer to sell and/or sell any diagnostic kits. Taiho confirms that
                it will
                not exercise such
                license and sublicense, unless and until the Agreement and/or its
                rights
                hereunder are
                terminated. In addition, Taiho agrees to comply with Section 24(f)
                of
                Response's agreement
                with USC dated April 19, 2000, entitled "Option and License Agreement,"
                as
                it applies to Taiho's exercise of its rights under this Item 5. Response
                will cooperate with Taiho
                as necessary to effectuate such license and sublicense and Taiho's
                exercise thereof.

            

    

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

        

      

      
        
        

        
          

        

      

      
        
        

      

    

    September
      29, 2004 
Page
      2

     

    
      	 	
              6.

            	
              The
                first (ii) clause in Paragraph 10(e) shall be replaced with: "(ii)
                if
                Taiho provides notice
                of the foregoing during the Term after the second year thereof,"
                and the
                sentence shall continue with "Response will negotiate in good faith
                a
                downward adjustment to the terms
                of this Agreement to reflect such competition as the parties reasonably
                agree and the obligation to purchase the Minimum Amount under paragraph
                4
                shall no longer apply." Except as set forth in this Item 6, Paragraph
                10(e) shall remain unchanged.

            

    

     

    
      	 	
              7.

            	
              In
                addition, in the event an in-vitro diagnostic ("IVD") form of any
                Testing
                Service becomes available in Japan, the obligation to purchase the
                Minimum
                Amount under Paragraph
                4 shall no longer apply.

            

    

     

    
      	 	
              8.

            	
              After
                October 1, 2005, Taiho shall have the right to terminate the Agreement
                upon six (6) months notice, in the event the underlying research
                of Taiho,
                including with its collaborators,
                using the DTP Platform has ended. In connection with such termination,
                the
                Parties may discuss the desirability of Taiho using Response's other
                technology platforms for its research; although it is understood
                neither
                Party shall be obligated by this
                Item 8 with respect to use of such other
                platforms.

            

    

     

    
      	 	
              9.

            	
              In
                the event of any termination or expiration of the Agreement, the
                Paragraphs set forth in Paragraph
                10(i) of the Agreement and Items 4 and 5 hereof shall survive any
                such
                expiration
                or termination.

            

    

     

    If
      you
      are in agreement with the foregoing, please execute one of the enclosed
      duplicate originals in
      the
      space below and return the signed version to me at your earliest
      convenience.

     

    
      	 	 	 	 
	 	
              Agreed
                to by:

            	 
	 	 	 
	 	 	 
	
            	
            		09/29/2004
	 	
              

              Kathleen
                Danenberg

              President
                and CEO

              Response
                Genetics, Inc.

            	 
	 	
            	 
	Agreed to by:	 	 
	 	 	 
	[***]	09/29/2004	 
	
              
                

              

              
                [***]
Director of Product Research &
                Licensing

              Taiho
                Pharmaceutical Co., Ltd.

            	 	 

    

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    September
      29, 2004
Page
      3

     

    In
      addition, Peter Danenberg and Kathleen Danenberg hereby confirm that the
      commitment stated
      in
      the letter dated July 23, 2001 between them and Taiho, attached as Schedule
      D to
      the Agreement, shall continue to apply during the Term as amended
      herein.

    
      	 	 	 	 	 
	 	 	 	 	 
		09/29/2004	 		09/29/2004
	
              

              Peter
                V.
                Danenberg

              Professor
                of Biochemistry and Molecular Biology

              University
                of Southern California

            	 	 	
              

              Kathleen
                Danenberg

              University
                of South California

            	 
	
            	 	 	
            	 

    

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.LICENSE
      AGREEMENT

     

    This
      License Agreement (the "Agreement")
      is
      dated
      as of the 23rd day of November, 2004 (the "Effective
      Date"), by
      and
      between Response Genetics, Inc., located
      at 1640 Marengo St., Los Angeles, California 90033 ("RGI") and Roche
Molecular
      Systems, Inc., located at 4300 Hacienda Drive, Pleasanton, California 94588
      ("RMS").

     

    WHEREAS
      RGI owns certain RGI Patent Rights (identified in Exhibit "1") and has
the
      right
      to grant licenses thereunder; and

     

    WHEREAS
      RMS owns certain patent rights, has developed certain technology, and
      possesses expertise relating to the preparation of assays;

     

    WHEREAS
      RGI has entered into and will continue to enter into collaborations with
      pharmaceutical companies in connection with the development by RGI of research
      assays
      (each an "RGI Assay");

     

    WHEREAS
      RMS and RGI wish to collaborate so that RMS will obtain access to the
      RGI
      Patent Rights and the RGI Assays so that RMS may develop, optimize, manufacture
      and sell assays for research, investigational and in vitro diagnostic use (
      "Optimized
      Assays"); and

     

    WHEREAS
      RMS wishes and intends to manufacture and sell the Optimized Assays
      developed hereunder in the Licensed Territories (as defined
      hereinafter),

     

    IT
      IS
      THEREFORE AGREED: 

     

    1.
      GENERAL
      DEFINITIONS

     

    1.1 Affiliate.
      The
      term
      "Affiliate" shall mean, with respect to any Person,
      any other Person that, directly or indirectly, controls, is controlled by or
      is
      under common control with, that Person, provided however, that in each case
      any
      such other Person
      shall be considered to be an Affiliate only during the time during which such
      control exists. For purposes of this definition, "control" (including, with
      correlative meaning,
      the terms "controlled by" and "under common control with"), as used with respect
      to any Person, shall mean the possession, directly or indirectly, of the power
      to direct
      and/or cause the direction of the management and policies of such Person,
      whether through the ownership of voting securities, by contract or otherwise.
      With regard
      to
      RMS, the term Affiliate shall not include Genentech, Inc., 1 DNA Way, South
      San
      Francisco, California 94080-4990, U.S.A. ("Genentech") or Chugai Pharmaceutical
      Co.,
      Ltd,
      1-9, Kyobashi 2-chome, Chuo-ku, Tokyo, 104-8301, Japan ("Chugai").

     

    1.2 Claim.The
      term
      "Claim" shall mean a claim of an issued patent which
      has
      not expired and which has not been disclaimed, canceled or held invalid or
      unenforceable
      by a court of competent jurisdiction.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    1.3 End
      Product.
      The
      term
      "End Product" shall mean any Optimized Assay
      sold for in vitro diagnostic use that is covered in whole or in part by a Claim
      included
      within the RGI Patent Rights.

     

    1.4 Field.
      The
      term
      "Field" shall mean the research, development, manufacture
      and sale of assays by RMS, including but not limited to the Optimized
Assays.

     

    1.5 Licensed
      Territories.
      The
      phrase "Licensed Territories" shall mean
      the
      United States and all foreign countries or regions worldwide.

     

    1.6 Net
      Sales.
      The
      phrase Net Sales shall mean the amounts invoiced for End Products by members
      of
      the RMS Group to purchasers and other transferees after deduction of volume
      discounts, sales rebates, reimbursements for returns, and sales taxes (e.g.,
      value added taxes) and other taxes directly linked to the sales (provided that
      such taxes are invoiced to and paid by such purchasers or other transferees),
      but excluding discounts, rebates, price reductions and/or credits to customers
      on account of settlement of complaints, less the following deductions for.
      a)
      "Sales
      Expenses" in the amount of [***] percent ([***]%), provided that this
      percentage shall be reduced in accordance with each general reduction by RMS
      of
such
      Sales Expenses in connection with the calculation of royalties payable with
      respect to
      the
      sale of diagnostic kits; b) "Reagent Rental Deduction" in the amount of
      [***]
      percent ([***]%), provided that this percentage shall be reduced in accordance
      with
      each
      general reduction by RMS of such Reagent Rental Deductions in connection with
      the calculation of royalties payable with respect to the sale of diagnostic
      kits; and c) deductions for "Third Party Royalty Expenses".

     

    Net
      Sales
      shall be determined from the books and records of RMS and its Affiliates.
      In the event that an End Product is sold together with one or more other
product(s)
      at a single price (a "Combination Product"), such single price shall be
allocated
      among the End Product(s) and the other product(s) in the Combination
Product
      based upon the relevant market prices for such products when sold separately.
      If
      any such product is not sold separately, RGI and RMS shall in good faith discuss
      and agree upon a fair market price for that product and that price shall be
      used
      to calculate the
      Net
      Sales.

     

    When
      End
      Products are not sold, or are not sold and itemized separately, but are
      otherwise transferred or sold together with one or more other products as part
      of a
      sales
      transaction, the Net Sales of such End Products shall be calculated according
      to
their
      sale prices when sold separately, or, if there are no such prices, then
      according to the average of prices at which products of the most similar kind
      and quality, sold in similar
      quantities, are then being offered for sale by RMS and/or its Affiliates. If
      a
      selling price
      cannot thus be determined, then it shall be the fair market value of the End
      Product in question.

     

    "Sales
      Expenses" shall mean a lump sum deduction in lieu of deductions for actual
      internal expenses of RMS or its Affiliates such as for (a) tariffs, duties
      and
      taxes imposed
      upon the production, sale, delivery or use of End Products (excluding taxes
      that
      are separately invoiced to end users, distributors or agents); (b) distribution
      and other customary expenses,
      such as freight, transportation and insurance expenses, and (c) cash discounts,
      retroactive price reductions or credits to customers on account of settlement
      of
      complaints.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    "Reagent
      rental expenses" shall mean a lump sum deduction of fees for all services which
      are included in reagent prices such as instrument service costs, instrument
      depreciation,
      finance costs, disposables and rental fees.

     

    "Third
      Party Royalty Expenses" shall mean royalties paid to Third Persons by
      RMS
      and/or its Affiliates to obtain rights and licenses under Blocking Third Party
      Intellectual
      Property, excluding any royalties paid to Third Persons that can be allocated
      to
      rights
      and licenses not directly necessary for RMS and its Affiliates to make, have
      made, use, import, offer to sell or sell End Products.

     

    "Blocking
      Third Party Intellectual Property" shall mean, with respect to any country
      in
      the Licensed Territories, patent rights in such country, owned or controlled
      by
      a Third Person, that cover specific reagents, assays, processes and/or platforms
      or any other technology required for the use, importation, manufacture, offer
      for sale or sale of an
      End
      Product, if the manufacture, use, importation, offer for sale or sale of such
      End Product would in the absence of a license granted by such Third Person,
      infringe such patent
      rights.

     

    1.7 RGI
      Patent Rights.
      The
      phrase "RGI Patents Rights" shall mean and
      include (i) all United States and foreign applications for patents listed in
      Exhibit
      "1".
      as
      well
      as all United States and foreign patents that have or may hereafter issue in
      respect of such applications for patents, and (ii) all applications for patents
      whose subject matter in whole or in part is entitled to the benefit of the
      filing date(s) of any of the
      applications for patents listed on Exhibit "1" and all United States and foreign
      patents that have or may hereafter issue in respect of such applications for
      patents, including
      in each case of the foregoing clauses (i) and (ii) of this Section 1.7, without
      limitation,
      all continuations, continuations-in-part, divisionals, substitutions, Patent
      Cooperation
      Treaty applications, United States provisional patent applications, continued
      prosecution applications, utility models, supplementary protection certificates,
      reexaminations,
      renewals, extensions and reissues thereof.

     

    1.8 Person.
      The
      term
      "Person" shall mean an individual or any legally recognized entity, including
      any corporation, partnership, limited partnership, limited liability company,
      association or trust.

     

    1.9 RGI
      Technical Information.
      The
      phrase "RGI Technical Information"
      shall mean RGI unpatented intellectual property, including
      know-how.

     

    1.10 RMS
      Group.
      The
      phrase "RMS Group" shall mean RMS and its Affiliates.

     

    1.11 RMS
      Technical Information.
      The
      phrase "RMS Technical Information"
      shall mean RMS unpatented intellectual property, including
      know-how.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    1.12
      Third
      Person.
      The
      phrase "Third Person" shall mean a Person other than RGI and members of the
      RMS
      Group.

     

    2.
      COLLABORATION

     

    2.1 Description
      of Cotlaboration.
      Subject
      to the other terms and conditions herein, RGI will collaborate exclusively
      with
      RMS in the area of commercial assay development related to the validation of
      genetic markers for pharmaceutical companies
      as follows. At such time as RGI validates a genetic marker for a pharmaceutical
      company, with respect to such marker's ability to aid in the prediction of
      a
      patient's therapeutic response to a pharmaceutical compound, RGI will provide
      RMS with the related RGI Assay, as well as relevant detailed information
      regarding RGI's collaboration
      with the said pharmaceutical company to the extent that that is authorized
      by
      the
      said pharmaceutical company, for the purposes described in Section 2.2
      below.

     

    2.2 With
      regard to the commercialization of the RGI Assays:

     

    (1) For
      those
      RGI Assays that meet RMS's customary criteria for commercialization, RMS shall
      make commercially reasonable efforts to enter into agreements with
      pharmaceutical companies to optimize the RGI Assays so that they may
      be
      used as commercial diagnostic assays. Through its purchase of the reagents
      as
      described in Section 2.7, RGI is hereby granted the right to use the Optimized
      Assays for research only. RMS will own all improvements or modifications made
      solely by RMS to the RGI Assays or RGI Patent Rights, including any such
      improvements to the Optimized Assays, and RMS retains the sole discretion as
      to
      any use of the said improvements or modifications;

     

    (2) RMS
      may
      sublicense or enter into contract manufacturing agreements with
      third parties to optimize and commercialize the RGI Assays, provided that RMS
      provides RGI with sixty (60) days written notice of such sublicense or contract
      manufacturing agreement, and further provided that the sublicensee or contract
      counter-party, as the case may be, agrees to all of the terms and conditions
      hereof pertaining
      to the protection of RGI Patent Rights and RGI Technical Information, including
      the confidentiality, indemnity, etc. provisions. Furthermore, all other terms
      and conditions
      of this Agreement shall apply to and in the event of any such sublicense or
      contract
      arrangement; or

     

    (3) In
      the
      event that RMS determines in good faith that an RGI Assay does not meet Roche's
      customary criteria for commercialization and that it is therefore commercially
      reasonable to make no effort to enter into an agreement with a pharmaceutical
      company in accordance with Section 2.2(1), and RMS chooses not to sublicense
      or
      contract in accordance with Section 2.2(2), then RGI shall be free, either
      alone
      or
      in collaboration with any counterparty of its choosing, to enter into agreements
      with
      pharmaceutical companies to improve, refine, and optimize the RGI Assay in
      question so that it may be used by RGI as a commercial diagnostic assay as
      part
      of RGI's
      diagnostic services, subject to any royalties, if any, payable under the terms
      of RGI's
      Diagnostic Service License Agreement effective November 16, 2004. RMS shall
      have
      no
      further rights in the particular RGI Assay or in any improvements made by RGI
      or
      any
      third party.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    2.3 Packaging
      and Labeling.
      RMS
      will
      design and develop all packaging,
      labels, and instructional material for any Optimized Assay that RMS or its
      Affiliates
      commercialize.

     

    2.4 Regulatory
      Approvals.
      RMS
      shall
      obtain any and all regulatory approvals
      required in order to commercialize End Products.

     

    2.5 Instrumentation.
      RMS
      shall
      provide RGI with up to [***] thermal cycler
      instruments ("RMS Instruments"), to be determined by RMS and RGI in good faith
      consultation during the term of this collaboration, in order to assist RGI
      in
      utilizing Optimized
      Assays. RGI may obtain support and training from RMS or its Affiliates on
such
      instruments at fees, terms and conditions discounted [***]% off of list prices.
      Title to the RMS Instruments shall at all times remain with RMS and at the
      expiration or termination of this Agreement RGI shall return the RMS Instruments
      as directed by RMS, provided, however, that RGI shall have the option to
      purchase any and all of the RMS Instruments at the lesser of (a) their
      respective depreciated values and (b) their respective
      market prices.

     

    2.6 Research
      Support.
      RMS
      shall
      provide research support to RGI in connection
      with the transfer of the Optimized Assay to RGI in the form of training and
      consulting
      services by RMS full-time employees. Such full-time employee support shall
      be
      based upon requirements, which shall be determined by RMS and RGI in good faith
      consultation,
      with reasonable final determinations to be made by RMS.

     

    2.7 Supply
      of Reagents.
      Research
      use only reagents for the Optimized
      Assay shall be provided by RMS to RGI at a cost to RGI of not more than $[***]
      per assay. For these purposes, an "assay" shall mean measurement of relative
      gene
      expression (by qRT PCR) of three genes and one constitutively expressed control
      gene
      with
      respect to a tissue specimen. The aforesaid price shall also cover all
reagents
      for all required run controls with regard to the specimens
      analyzed.

     

    3.
      GRANTS,
      ETC

     

    3.1 License
      Grant to RMS.
      Subject
      to the terms and conditions of this Agreement, including Section 2.2, RGI hereby
      grants to RMS Group under the RGI Patent
      Rights an exclusive license in the Field in the Licensed Territories to make,
      have made,
      use, practice, import, offer to sell and sell End Products.

     

    3.2 License
      Grant to RGI. Subject
      to the terms and conditions of this Agreement, RMS hereby grants to RGI a
      license to the Optimized Assays. This grant to RGI
      shall
      be for its internal use in RGI's diagnostic service business and during the
      term
of
      the
      collaboration shall be without royalty, but without any rights to sublicense
      or
transfer
      to any third party. After the termination of the collaboration, the Optimized
      Assays
      will be licensed to RGI for its internal diagnostic services for a royalty
      of
      [***] percent ([***]%) of [***] percent ([***]%) of Net Service Revenue as
      that
      term is defined in the
      Expanded PCR Diagnostic Services Agreement by and between RMS and RGI,
effective
      November 16, 2004, without right of sublicense or transfer to third parties.
      For
the
      avoidance of doubt, RGI shall not be granted the right to resell, transfer
      or
      otherwise provide
      the Optimized Assays to any third party. Further, RGI is not granted any right
      to make, have made, import, offer to sell or sell any Optimized
      Assays.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    3.3 Covenant
      Not to Grant Further Licenses.
      RGI
      covenants and agrees
      not to grant any additional licenses in the Field under the RGI Patent Rights
      to
      any Third Person without the prior written consent of RMS, which consent shall
      not be unreasonably
      withheld.

     

    3.4 Patent
      Prosecution and Maintenance, Etc. Each
      party shall have
      the
      exclusive right to prosecute and maintain the United States and foreign
      applications for patents and patents comprising its respective patent rights
      using counsel of its choice at its expense. The costs and expenses of all
      interferences will be considered
      prosecution expenses. RGI shall make reasonable efforts to provide RMS
with
      copies of relevant documentation so that RMS may be apprised of the continuing
      prosecution of the RGI Patent Rights and any challenges by Third Persons to
      the
validity
      or enforceability of the RGI Patent Rights. With respect to documentation
relating
      to prosecution of the RGI Patent Rights, RMS may comment upon such documentation
      provided such comments are made sufficiently in advance of any deadline
      for filing a response. All such documentation shall be treated as the
Proprietary
      Information of RGI and shall be held in confidence in accordance with the
      provisions of Article 5 herein. Should RGI decide not to make commercially
      reasonable efforts to preserve the RGI Patent Rights, or not to seek patent
      protection or to discontinue patent protection for the RGI Patent Rights, RGI
      shall promptly notify RMS of
      its
      decision and grant RMS the right to prepare, file and prosecute or have
      prepared, filed
      or
      prosecuted patents and patent applications directed to the RGI Patent
      Rights.

     

    3.5 Enforcement
      Rights.
      RGI
      retains the right to assert and enforce against
      any and all third parties suits for infringement of the RGI Patent Rights.
      RMS
      retains the right to assert and enforce against any and all third parties suits
      for infringement of the RMS patent rights. If RGI declines to enforce its rights
      in the RGI Patent Rights, then RMS may proceed to enforce those rights against
      infringement. The party prosecuting any such infringement shall pay for the
      costs of such proceedings, control the conduct of such proceedings, enforce
      the
      rights in question vigorously,
      and recover any awards made in such proceedings. The non-enforcing party
agrees
      to
      cooperate reasonably in such proceedings, and the enforcing party will pay,
      and
      will hold the non-enforcing party harmless from, any costs and expenses incurred
      by
      the
      non-enforcing party as a result of any such action.

     

    3.6 Deliveries
      of Files, Etc.
      Within
      thirty (30) days after the Effective Date,
      RGI
      shall make available to RMS copies of all required files, documents and records
      of RGI regarding the RGI Patent Rights as of the Effective Date. RGI shall
      also
provide
      RMS with appropriate technical consulting services, as reasonably requested
      by
      RMS, to help RMS in its understanding, utilization and implementation of the
      RGI
      Patent Rights,
      from time to time at no additional charge to RMS. RMS shall provide RGI with
      appropriate
      technical consulting services, as reasonably requested by RGI, to help RGI
      in
      its understanding, utilization and implementation of the Optimized Assays,
      from
      time to
      time
      at no additional charge to RGI.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

    4.
      REPRESENTATIONS,
      WARRANTIES AND INDEMNITIES

     

    4.1 Representations
      and Warranties of RMS.
      RMS
      hereby represents, warrants and covenants to RGI that:

     

    (a) RMS
      is a
      corporation duly organized, validly existing and in good standing
      under the laws of Delaware, with full power to carry on its business and
      activities as now being conducted;

     

    (b) This
      Agreement has been duly authorized, executed and delivered by RMS and represents
      its binding obligation, enforceable against it in accordance with its
      terms
      and conditions. RMS has the corporate power and authority to enter into this
      Agreement
      and to perform its obligations hereunder. No other act, approval or proceeding
      on the part of RMS is or will be required to authorize the execution and
      delivery of this Agreement, or the consummation of the transactions contemplated
      hereby;
      and

     

    (c) The
      execution and delivery by RMS of this Agreement will not, and the fulfillment
      of
      and compliance by RMS with the terms, conditions and provisions hereof
      will not: (i) conflict with any of the terms, conditions or provisions of the
      articles of incorporation
      or by-laws of RMS or of any of its Affiliates, (ii) violate any term, condition
      or provision of, or require any consent, authorization or approval under, any
      judicial or arbitration
      judgment, order, award, writ, injunction or decree applicable to RMS or any
      of
      its Affiliates, or (iii) conflict with, result in a breach of, constitute a
      default under (whether with
      or
      without the giving of notice or the lapse of time or both), or accelerate or
      permit the
      acceleration of the performance required by, or require any consent,
      authorization or approval under any document, instrument, agreement or license
      to which RMS or any of its
      Affiliates is a party, or by which RMS or any of its Affiliates is bound, or
      to
      which any of
      the
      assets or properties of RMS or of any of its Affiliates are
      subject.

     

    4.2 Representations
      and
      Warranties
      of RGI.
      Each
      Person comprising
      RGI hereby represents, warrants and covenants to RMS that:

     

    (a) RGI
      is an
      entity duly organized, validly existing and in good standing
      under the laws of the state of its organization, with full power to carry on
      its
business
      and activities as now being conducted;

     

    (b) This
      Agreement has been duly authorized, executed and delivered by RGI and represents
      its binding obligation, enforceable against it in accordance with its
      terms
      and conditions. RGI has the corporate power and authority to enter into this
      Agreement
      and to perform its obligations hereunder. No other act, approval or proceeding
      on its part is or will be required to authorize the execution and delivery
      of
      this Agreement, or the consummation of the transactions contemplated
      hereby;

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

    (c) The
      execution and delivery by RGI of this Agreement will not, and the
      fulfillment of and compliance by it with the terms, conditions and provisions
      hereof will
      not:
      (i) conflict with any of the terms, conditions or provisions of the articles
      or
      certificate of organization or by-laws of it or any of its Affiliates, (ii)
      violate any term, condition
      or provision of, or require any consent, authorization or approval under, any
      judicial
      or arbitration judgment, order, award, writ, injunction or decree applicable
      to
      it or any of its Affiliates, or (iii) conflict with, result in a breach of,
      constitute a default under (whether with or without the giving of notice or
      the
      lapse of time or both), or accelerate or permit the acceleration of the
      performance required by, or require any consent, authorization or approval
      under
      any document, instrument, agreement or license to which
      it
      or any of its Affiliates is a party, or by which it or any of its Affiliates
      is
      bound, or to
      which
      any of its assets or properties or the assets or properties of any of its
      Affiliates are subject;

     

    (d) RGI
      is
      the sole and exclusive owner of, or has licensed rights in and
      to,
      the RGI Patent Rights and has the lawful right (with the express written
      permission from the University of Southern California) to grant to RMS Group
      the
      license and rights granted in Section 3.1 herein;

     

    (e) To
      the
      best of its knowledge, the RGI Patent Rights are valid and enforceable and
      RGI
      has not taken or failed to take any action which might result in their
      invalidity and/or unenforceability against Third Persons, and RGI has received
      no information
      or claim to the effect that the RGI Patent Rights are going to be challenged,
      are
      invalid or are unenforceable;

     

    (f) RGI
      has
      not received a notice or claim to the effect that the inventions subject to,
      claimed by, or included within the RGI Patent Rights infringe, violate or
      misappropriate the patent or trade secret rights of any Third Person;
      and

     

    (g) Exhibit
      "2" to this Agreement is a schedule disclosing, to the extent that
      RGI
      is permitted to, all licenses or contracts of RGI with Third Persons, in effect
      prior
      to
      the Effective Date, in which RGI has granted licenses of the RGI Patent Rights.
      There
      are
      no licenses or contracts with Third Persons that are not listed in Exhibit
      "2"
      that have a material adverse effect on the rights granted to RMS in this
      Agreement.

     

    4.3
      Indemnification.

     

    (a) RMS
      shall
      indemnify, hold harmless and defend RGI, its directors, officers,
      shareholders, employees, representatives, attorneys, Affiliates and agents
      (each
      such Person a "RGI Indemnitee") from and against any and all claims, suits,
      losses,
      damages, obligations, costs, fees and expenses (including reasonable attorneys'
      and experts' fees and court costs) suffered or incurred by any RGI Indemnitee
      arising out of, resulting from or otherwise concerning a breach by RMS of
any
      of
      RMS's representations and warranties contained in this Article 4.

     

    (b) RGI
      shall
      indemnify, hold harmless and defend RMS Group, their respective
      directors, officers, shareholders, employees, representatives, attorneys,
Affiliates
      and agents (each such Person a "RMS Indemnitee") from and against any and
all
      claims, suits, losses, damages, obligations, costs, fees and expenses (including
      reasonable
      attorneys' and experts' fees and court costs) suffered or incurred by any
RMS
      Indemnitee arising out of, resulting from or otherwise concerning a breach
      by
      RGI of
      any of
      RGI's representations and warranties contained in this Article 4.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

     

    (c)
      Any
      RGI Indemnitee or RMS Indemnitee, as the case may be, seeking to be held
      harmless, defended and indemnified in accordance with the provisions of Section
      (a) or (b) of this Section 4.3 shall promptly notify RMS or RGI, as appropriate
      (the "Indemnitor"), of any claim or suit brought against such RGI Indemnitee
      or
      RMS
      Indemnitee in respect of which such RGI Indemnitee or RMS Indemnitee intends
      to
      invoke the provisions of this Section 4.3, although the failure to so notify
      the
Indemnitor
      shall not release such Indemnitor from its obligations under this Section 4.3
      unless such Indemnitor shall have been materially prejudiced by such failure.
      Such Indemnitor
      shall indemnify, hold harmless and defend such RGI Indemnitee or RMS Indemnitee,
      as the case may be, as above provided, and shall keep such RGI Indemnitee or
      RMS
      Indemnitee fully informed of the Indemnitor's defense and/or settlement
      of such claim or suit. The RGI Indemnitee or RMS Indemnitee, as the case
may
      be,
      shall cooperate reasonably in the defense of such claim or suit, and shall
      have
the
      right, but no obligation, to participate in the defense thereof with counsel
      of
      such Person's choice at such Person's expense.

     

    4.4 RMS
      shall
      indemnify, hold harmless and defend the RGI Indemnitees
      from and against any and all claims, suits, losses, damages, obligations, costs,
      fees and expenses (including reasonable attorneys and experts fees and court
      costs) suffered or incurred by any RGI Indemnitee, arising out of, resulting
      from, or otherwise concerning the development, manufacture, use or sale of
      End
      Products by RMS or any RMS Affiliate or any sub-licensee of any RMS Group
      member, for any injury
      of
      any kind unless such claim or damage (a) is the direct result of a negligent
      act
or
      omission by RGI or (b) asserts that the RGI Patent Rights or RGI Technical
      Information
      infringes or misappropriates the rights of any Third Persons.

     

    4.5 Survival.
      The
      provisions of this Article 4 shall survive the expiration
      or termination of this Agreement in accordance with their respective terms
      and
      conditions.

     

    5.
      PROPRIETARY
      INFORMATION

     

    5.1
      Proprietary
      Information.
      Subject
      to the terms and conditions of this Article 5, RGI and the members of the RMS
      Group, respectively, will treat and maintain the confidential and proprietary
      business, patent prosecution and other data and information, including RGI
      Technical Information, RMS Technical Information, and the non-public information
      and documentation supplied by RMS to RGI and by RGI to RMS
      pursuant to this Agreement (collectively, the "Proprietary Information"), of
      the
      other party
      in
      confidence, and will only use such Proprietary Information in furtherance of
      this Agreement and the transactions and matters contemplated
      herein.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    

     

    5.2 Labeling.
      The
      receiving party shall include all proprietary and legal notices of the
      disclosing party on all copies of the Proprietary Information of the disclosing
      party, and shall not remove, delete or omit any proprietary or legal notices
      from the Proprietary Information of the disclosing party.

     

    5.3 Confidential
      Disclosure.
      Notwithstanding anything herein to the contrary,
      RGI and RMS each may disclose Proprietary Information of the other party to
      its
      respective employees, agents, consultants, contractors and Affiliates, as the
      case may be, provided that each such Person first undertakes to be likewise
      bound by the duty and obligation of confidentiality and the restrictions on
      use
      agreed to herein.

     

    5.4 Limitations.
      Nothing
      contained herein shall in any way restrict or impair
      the right of RGI or RMS to use, disclose or otherwise deal with, as appropriate,
      any
      Proprietary Information of the other party:

     

    (1) that
      the
      recipient can demonstrate was previously known to it;

     

    (2) that
      the
      recipient can demonstrate by written records was independently developed
      by it without access to or use of the Proprietary Information of the disclosing
      party;

     

    (3) that
      is
      publicly known when thus used, disclosed or otherwise dealt with, other
      than through acts or omissions of the recipient;

     

    (4) that
      is
      lawfully obtained by the recipient without confidentiality or use restrictions
      from sources independent of the disclosing party;

     

    (5) that
      is
      required to be disclosed to a governmental entity or agency in connection with
      seeking any governmental or regulatory approval, or pursuant to the lawful
      requirement or request of a governmental entity or agency; and/or

     

    (6) that
      the
      recipient is required to disclose pursuant to lawful legal process or other
      applicable law.

     

    5.5 Return
      of Proprietary Information.
      Upon
      the
      expiration or termination
      of this Agreement, at the written request of the disclosing party, the recipient
      party
      shall, within thirty (30) days following receipt of the request, (a) destroy
      or
      return to the
      disclosing party all Proprietary Information received from the disclosing party,
      and (b)
      provide the disclosing party with a written notice that the Proprietary
      Information has been
      returned or destroyed. The recipient party may, however, retain one copy of
      such
      Proprietary Information for archival purposes in nonworking confidential
      files.

     

    5.6 Equitable
      Relief.
      The
      parties agree that a remedy at law for breach
      of
      Sections 5.1 or 5.5 may be inadequate, and that the party seeking to enforce
      Sections
      5.1 or 5.5 shall be entitled, in addition to such other remedies as it may
      have
      at law
      or
      otherwise, to seek temporary or permanent injunctive relief and/or specific
      enforcement for any breach or threatened breach thereof by the other party
      without proof of any actual damages that have been or may be caused by such
      a
      breach.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    

    5.7
      Survival.
      The
      provisions of this Article 5 shall survive the expiration
      or termination of this Agreement in accordance with their respective terms
      and
      conditions.

     

    6.
      ROYALTIES,
      ETC.

     

    6.1 Running
      Royalties.
      In
      consideration of the grant set forth in Section
      3, subject to the terms and conditions of this Agreement including Sections
      6.2
and
      6.3
      below, RMS shall pay to RGI a royalty of [***] percent ([***]%) of [***] percent
      ([***]%) of Net Sales of the RMS Group for End Products. Notwithstanding
the
      foregoing, in no event shall RMS pay any royalty to RGI for any sale or transfer
      of reagents
      to RGI in accordance with Section 2.7.

     

    6.2 Third
      Party Licenses.
      If
      the
      RMS Group determines that any End Product
      or the use thereof infringes claims of an issued patent or patents other than
      those in the RGI Patent Rights, RMS may negotiate with the owner of such
      patent(s) for a license on such terms as RMS reasonably deems
      appropriate.

     

    6.3 Affiliates.
      The Running Royalties provided in Article 6 shall be payable
      by RMS with respect to the activities of RMS's Affiliates as well.

     

    6.4 Statements
      and Payments.
      RMS
      shall
      deliver a quarterly statement
      to RGI, indicating the Running Royalty payments due to RGI in respect of each
      calendar quarter after the Effective Date, accompanied by payment of the
applicable
      Running Royalty due. Each quarterly statement shall state the number of
End
      Products sold or otherwise conveyed by RMS and its Affiliates to third parties
      for such fiscal quarter and the Net Sales in that regard. The first quarterly
      statement and payment shall be due within sixty (60) days after the close of
      the
      first calendar quarter following the Effective Date. Subsequent quarterly
      statements shall be due within sixty (60) days following the close of each
      subsequent calendar quarter.

     

    6.5 Audits.
      RMS
      and
      its Affiliates shall maintain regular and complete records
      for a period of two (2) years after the later of (x) the receipt by RGI of
      the
      quarterly statement to which they pertain and (y) the expiration of the calendar
      quarter to which they pertain, sufficient to enable verification of the accuracy
      of all statements and reports made by RMS. Such records shall be maintained
      at
      RMS's regular place of business and shall be available for inspection and
      auditing by RGI's outside accountants
      on thirty (30) days notice during normal business hours; provided, however,
      that
      RGI shall not cause such an inspection and/or audit to occur more than once
      in
      any twelve (12) month period, and provided further that all such inspections
      and
audits
      shall be conducted so as not to unreasonably interfere with RMS's regular
      business activities. Should any such audit reveal a payment short fall by RMS,
      the amount
      of
      the short fall shall be paid promptly by RMS after the discovery thereof,
      together with interest thereon calculated at the rate of one percent
(1%)
      per
      month from the
      date
      such payment should have been paid, or the maximum rate permitted by law if
      such
      rate
      shall be lower than one percent (1%) per month.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

    

    6.6
      Nondisclosure.
      RGI
      shall
      hold the statements and reports contemplated
      in Section 6.4 and any information acquired during any inspection and audit
      conducted in accordance with Section 6.5 in confidence, and shall use such
      statements,
      reports and information solely for the purposes of (i) collecting any Running
      Royalties
      due it, and/or (ii) complying with the terms and conditions of this Agreement.
      Nothing in this Section 6.6 shall be construed to preclude RGI from making
      any
      disclosures required by any governmental laws or regulations or by judicial
      process.

     

    7.
      TERMINATION

     

    7.1 Agreement
      Expiration.
      Except
      as
      otherwise provided in this Article
      7, this Agreement, including the license grants contained in Article 3 herein,
      shall continue until the date on which each and every application for patent
      and
      Claim of the RGI
      Patent Rights has (i) expired, (ii) been disclaimed, (iii) been canceled,
      abandoned or terminated, or (iv) been held invalid by a court of competent
      jurisdiction, from which no further appeal is possible or has been taken within
      the time period provided.

     

    7.2 Termination
      for Material Breach.
      Either
      party may terminate this Agreement, including the license grants contained
      in
      Article 3 herein, in the event that the other party (the "Breaching Party")
      materially breaches a material provision of this Agreement, which breach is
      not
      substantially cured by the Breaching Party within one hundred
      eighty (180) days after written notice of such breach by the terminating party
      to the Breaching Party, provided that in the event of a material breach by
      RMS
      of any then undisputed payment obligation to RGI under Article 6 hereof, the
      applicable period within which there shall be an opportunity to cure such a
      breach shall be thirty (30) days after
      the
      date of such breach. Termination of this Agreement based upon a material
breach
      hereof shall be without prejudice to any other rights and remedies that the
      terminating party may have as a result of the default.

     

    7.3 Termination
      for Cause.
      Either
      party may terminate this Agreement
      upon sixty (60) days written notice to the other party in the event of any
      of
      the following events: (a) Kathy Danenberg ceases to be an executive officer
      of
      RGI, provided
      that in such case, thirty (30) days written notice shall be deemed adequate;
      (b)
RGI
      is
      dissolved or enters into a liquidating bankruptcy proceeding; or (c) RMS and
      its
      Affiliates discontinue its and their programs (which RMS represents is currently
      known within RMS as SynergysDx) to commercialize diagnostics via collaboration
      with third party pharmaceutical companies with respect to the development of
      companion diagnostics for personalized medicine.

     

    7.4 Termination
      on Notice.
      Neither
      party may terminate this Agreement,
      except pursuant to the provisions of Sections 7.2 or 7.3 hereof, during a period
      of two (2) years from its Effective Date (the "Initial Term"). Thereafter,
      the
      Term of this Agreement shall automatically renew for one year periods, subject
      to the following termination provisions:

     

    (a)
      either party may terminate this Agreement after the Initial Term upon
      sixty (60) days written notice to the other party, provided, however, that
      any
      such termination
      under this Section 7.4(a) shall be as to collaboration obligations, set out
      in
      Sections 2.1 and 2.2, arising thereafter and shall not affect any pre-existing
      rights, licenses or obligations of the parties in relation to transactions
      with
      Third Persons or otherwise concerning any RGI Assays or Optimized Assays
      developed up to the date of termination.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

    

     

    (b) RMS
      may
      terminate this Agreement, including the provisions of Section
      3.1, after the Initial Term upon sixty (60) days written notice to
      RGI.

     

    (c) if
      a
      collaboration agreement with a third party pharmaceutical company
      cannot be concurrently terminated and therefore requires the participation
      of
RGI
      and
      RMS, the Term of this Agreement shall be extended so as to meet the requirements
      of such third party pharmaceutical company collaboration
      transaction.

     

    7.5
      Effects
      of Termination.
      Termination
      of this Agreement for any reason
      shall not release either party from any liabilities or obligations set forth
      in
      this Agreement
      which (i) the parties have expressly agreed shall survive any such termination,
      (ii) remain to be performed, or (iii) by their nature are intended to be
applicable
      following any such termination (e.g., Sections 2.7, 5, 10.3).
      Moreover,
      after Termination, RMS shall continue to supply to RGI, in accordance with
      Section 2.7 hereof,
      reagents that have been developed by RMS, for research purposes with respect
      to
      specific RGI collaborations with pharmaceutical companies, for the lesser of
      (a)
      the duration
      of then ongoing pharmaceutical research by RGI in that regard, and (b) five
      (5)
years.

     

    8.
      NOTICES

     

    Any
      notice given pursuant to this Agreement shall be in writing, and shall be deemed
      to have been duly given if delivered in person or sent by confirmed facsimile
      transmission
      or by certified, registered or overnight express mail or courier service,
postage,
      mailing and delivery expenses prepaid, to the address or facsimile number which
      the party to be notified has specified in writing to the other parties hereto,
      from time
      to
      time, as the address or facsimile number to which notices and requests are
      to be
delivered
      to it under this Agreement. A notice shall be considered to be effective upon
      actual receipt by the party to be notified. Any party may amend its address
      or
      facsimile number for notices by so notifying the other parties in writing of
      such change. The addresses
      and facsimile numbers for notices to each party are as follows:

     

    
      
        	
                If
                  to RGI:

              	
                If
                  to RMS:

              
	 	 
	
                Response
                  Genetics, Inc.

              	
                Roche
                  Molecular Systems, Inc.

              
	
                1640
                  Marengo Street

              	
                4300
                  Hacienda Drive

              
	
                Los
                  Angeles, CA 90033

              	
                Pleasanton,
                  California 94588

              
	
                Attn:
                  Kathleen Danenberg, CEO

              	
                Attention:
                  General Counsel

              
	 	 
	
                Fax:
                  (323)  224-3096

              	
                Fax:
                  (510)  814-2852

              

      

    

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        13

        
          

        

      

      
        
        

      

    

     

    9. WAIVER
      OF CONSEQUENTIAL DAMAGES. ETC.

     

    Except
      as
      otherwise contemplated in Articles 4, 5 and 9 of this Agreement, neither party
      shall be liable for indirect, consequential or punitive damages (including
      loss
      of
      income, profits or goodwill) arising under, relating to or otherwise concerning
      this Agreement
      whether based on an action or claim in contract, equity, negligence, tort
      (except for intentional misconduct) or otherwise, and each party hereby waives
      any claims
      with respect to such types of damages. RGI and RMS expressly acknowledge
that
      the
      exclusions contained in this Section have been the subject of active and
      complete negotiation between the parties and represent the parties' agreement
      based upon
      the
      level of risk to RMS and RGI associated with their respective obligations under
      this
      Agreement and the payments provided to RGI hereunder.

     

    10. GENERAL
      PROVISIONS

     

    10.1 Assignment;
      Binding Effect. Etc. This
      Agreement shall be binding
      upon and inure to the benefit of RGI and RMS and their respective permitted
      successors and assigns. RMS may assign its rights and licenses under this
      Agreement to any Affiliate or to any successor to all or substantially all
      of
      the business or assets of RMS without the prior written consent of RGI, provided
      such Affiliate or successor assumes in writing the obligations of RMS under
      this
      Agreement. Affiliates of RMS and of
      RGI,
      RMS Indemnitees, and RGI Indemnitees are intended third party beneficiaries
      of
this
      Agreement to the extent expressly provided herein. Any permitted assignment
      or
transfer
      of this Agreement by either party shall not relieve or release such party from
      any
      of
      its duties or obligations under this Agreement. RGI may assign or transfer
      the
RGI
      Patent Rights to any successor to all or substantially all of the business
      assets of RGI. If RGI wishes to assign this Agreement to any other party, RGI
      shall first notify RMS, and the parties shall discuss the proposed assignment
      in
      good faith for a period of
      not
      more than 14 days in order to avoid assignment of this Agreement to a competitor
      of RMS or to any party that could not reasonably fulfill the obligations of
      RGI
      hereunder. Each
      and
      every permitted successor and assign to or of the interests of either party
      to
      this Agreement shall hold such interests subject to the terms, conditions and
      provisions of this Agreement.

     

    10.2 Entire
      Agreement.
      This
      Agreement constitutes the full and entire understanding
      and agreement between the parties with regard to the subject matter hereof,
      and supersedes all prior or contemporaneous proposals, oral or written,
      understandings, representations, conditions and other communications between
      the
parties
      relating to such subject matter. Amendments hereof shall not be binding upon
      either
      party unless expressly agreed to in writing by both parties.

     

    10.3 Governing
      Law.
      This
      Agreement and the rights and obligations of the
      parties hereunder shall be governed by and interpreted in accordance with the
      laws of
      the
      State of California, except that its conflict of laws rules shall not apply.
      The
parties
      hereby consent to the personal jurisdiction of, and agree that any legal
proceeding
      with respect to or arising under this Agreement shall be brought exclusively
      in
      a state court of the State of California or a United States District Court
      sitting in California
      if such court has subject matter jurisdiction.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        14

        
          

        

      

       

    

     

    10.4 Interpretation.
      In
      any
      interpretation of this Agreement, it shall be deemed
      that this Agreement was prepared jointly by the parties, and no ambiguity shall
      be
      construed or resolved against either party on the premise or presumption that
      such party was responsible for drafting this Agreement.

     

    10.5 Severability.
      If
      any
      provision of this Agreement is declared or found to be illegal, unenforceable
      or
      void, then both parties shall be relieved of all obligations arising under
      such
      provision, but only to the extent that such provision is illegal,
      unenforceable or void. Further, this Agreement shall be deemed amended by
modifying
      such provision to the extent necessary to make it legal and enforceable while
      preserving
      its intent or, if that is not possible, by substituting therefor another
      provision that is legal and enforceable and achieves the same intended
      objective. Each provision not so affected shall be enforced to the extent
      permitted by law.

     

    10.6 Independent
      Contractors.
      The
      parties to this Agreement are independent contractors and this Agreement shall
      not be construed to create any partnership,
      franchise, fiduciary or employment relationship. In addition, nothing in this
      Agreement
      shall be deemed to appoint or authorize one party to act as an agent or
other
      representative of the other party or to assume or incur any liability or
      obligation in the
      name
      of or on behalf of the other party.

     

    10.7 Singular/Plural.
      Whenever
      in the context it appears appropriate, each term stated either in the singular
      or the plural shall include both the singular and the
      plural.

     

    10.8 Incorporation
      of Recitals and Exhibits.
      The
      recitals contained in this
      Agreement and the exhibits attached hereto are hereby incorporated into this
      Agreement and made a part hereof.

     

    10.9 Headings.
      Article,
      section and subsection headings in this Agreement
      are included for convenience of reference only and shall not constitute a
part
      of
      this Agreement for any other purpose or be given any substantive
      effect.

     

    10.10 Counterparts.
      This
      Agreement and any amendments, waivers, or consents
      hereto may be executed in any number of counterparts, and by different
parties
      in separate counterparts, each of which when so executed and delivered shall
      be
      deemed an original, but all such counterparts together shall constitute but
      one
      and the
      same
      agreement.

     

    10.11 Media
      Releases.
      All
      media
      releases, public announcements and public disclosures by RGI or members of
      the
      RMS Group shall be coordinated with and approved
      in writing by the other party prior to the release thereof.

     

    10.12 Force
      Majeure.
      If
      the
      performance of this Agreement or any obligation
      hereunder is prevented or interfered with by reason of fire or other casualty
      or
      accident, strikes or labor disputes, war or other violence, any law, order,
      proclamation, regulation, ordinance, demand or requirement of any governmental
      agency, or any other
      act
      or condition whatsoever beyond the reasonable control of the parties, the party
      whose performance is so affected, upon giving prompt notice to the other party,
      shall be excused
      from such performance or obligation to the extent and for the duration that
      it
      is so affected. However, the party so affected shall take all reasonable steps
      to avoid or remove
      such conditions and causes of nonperformance, and shall resume performance
      hereunder
      with dispatch when such causes are removed.

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        15

        
          

        

      

       

    

     

    10.13 Further
      Acts.
      Each
      party shall do, or cause to be done, all such further
      acts, and shall execute,.acknowledge and deliver, or cause to be executed,
      acknowledged and delivered, any and all such further documentation as the other
      party reasonably requires to carry out the purposes of this
      Agreement.

     

    10.14 Waiver.
      A
      waiver
      by either of the parties of any of the covenants, conditions or agreements
      affecting the other party or any breach thereof shall not be construed to be
      a
      waiver of any succeeding breach thereof or of any other covenant, condition
      or agreement contained herein.

     

    10.15 Performance
      by Affiliates.
      To
      the
      extent that any term or provision
      of this Agreement contemplates, permits or requires performance by any Affiliate
      of a party, such party shall cause such Affiliate to perform each and every
      obligation of such party under this Agreement in accordance with the terms
      and
conditions
      hereof, provided that any such performance shall not relieve the party hereto
      of
      its
      own obligations and duties hereunder.

     

    IN
      WITNESS WHEREOF, the
      parties have executed this Agreement effective
      as of the Effective Date.

     

    
      	RESPONSE
              GENETICS, INC.	 	ROCHE
              MOLECULAR SYSTEMS, INC.
	 	 	 	 
	 	 	 	
            
	By:  		 	By:
	
	Title 	
              
PRESIDENT
              & CEO	 	Title	
              
SVP
              Commercial Operations

     

    
      	 	 	 	 
	 	 	 	
              

            

    

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        16

        
          

        

      

      
        
        

      

    

     

    EXHIBIT
      "1" 

     

    RGI
      PATENT RIGHTS

    
      	
              U.S.
                Application or Patent
                Number

            	 	
              Title

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	
               

            
	
              [***]

            	 	
              [***]

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	
               

            
	
              [***]

            	 	
              [***]

            
	 	 	
               

            
	
              Foreign
                Applications

            	 	
              Title

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	 
	
              [***]

            	 	
              [***]

            

    

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

    

    
      
        
        

      

      
        
        

        
          

        

      

       

    

     

    
      	
              Foreign
                Applications

            	 	
              Title

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	 
	
              [***]

            	 	
              [***]

            
	 	 	 
	
              [***]

            	 	
              [***]

            

    

     

    Portions
      of this Exhibit were omitted and have been filed separately with the Secretary
      of the Commission pursuant to the Company’s application requesting confidential
      treatment under Rule 406 of the Securities Act.

    
      
        
        

      

      
        
        

        
          

        

      

       

    

     

    EXHIBIT
      "2" 

    
LIST
      OF LICENSES AND CONTRACTS

     

    
      
        
          	1.	
                  [***]

                

        

      

    

     

    
      
        
          	2.	
                  [***]

                

        

      

    

     

    
      
        
          	3.	
                  [***]

                

        

      

    

     

    
      Portions
        of this Exhibit were omitted and have been filed separately with the Secretary
        of the Commission pursuant to the Company’s application requesting confidential
        treatment under Rule 406 of the Securities Act.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]